RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Phathom Pharmaceuticals Stock

Phathom Pharmaceuticals Market capitalization 2024

Phathom Pharmaceuticals Market capitalization

824.73 M USD

Ticker

PHAT

ISIN

US71722W1071

WKN

A2PT0F

In 2024, Phathom Pharmaceuticals's market cap stood at 824.73 M USD, a 80.27% increase from the 457.5 M USD market cap in the previous year.

The Phathom Pharmaceuticals Market capitalization history

YEARMarket Capitalization (undefined USD)
20230.55
20220.45
20211.1
20201.22
20190.62
2018-

Phathom Pharmaceuticals Aktienanalyse

What does Phathom Pharmaceuticals do?

Phathom Pharmaceuticals Inc. is a pharmaceutical company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. The company is headquartered in Florham Park, New Jersey and was founded in 2016. The company's business model is focused on utilizing its innovative technology and expertise in the medical treatment of gastrointestinal disorders to improve the lives of patients. It works closely with doctors and hospitals to ensure that its products are developed to the highest standards. The company is divided into different business segments to enable optimal patient care and market penetration. The key business segments are: 1. Gastroesophageal reflux disease Phathom has developed a medication called Vonoprazan for the treatment of gastroesophageal reflux disease. This common condition occurs when stomach acid flows back into the esophagus, causing pain, inflammation, and heartburn. The medication blocks the production of stomach acid, thus helping to relieve the symptoms of reflux disease. 2. Helicobacter pylori infection The company has also developed a medication called Ryzodeg for the treatment of Helicobacter pylori infection. This infection, caused by a type of bacteria, can lead to stomach ulcers and other gastrointestinal disorders. Ryzodeg is a combination of an antimicrobial substance and a proton pump inhibitor, which together are more effective than individual medications. 3. Eosinophilic esophagitis Phathom is currently developing a medication for the treatment of eosinophilic esophagitis (EoE), an allergic inflammation of the esophagus that can cause difficulty swallowing, pain, and diarrhea. The medication is currently in the clinical development phase and could soon be on the market. Phathom Pharmaceuticals was founded by a group of experienced executives from the pharmaceutical and biotech industry, including CEO Dr. Azmi Nabulsi and COO Dr. Tuan Ha-Ngoc. Both have extensive experience in the development and marketing of medications and contribute their expertise to the company's management. The company also specializes in partnerships with other pharmaceutical companies and clinical research institutions to advance its research and development. For example, the company has entered into a strategic partnership with Takeda Pharmaceuticals to advance the development and marketing of Vonoprazan. Phathom Pharmaceuticals is a promising company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. With its innovative technology and experienced management, the company is expected to continue growing in the future and help improve the health of patients around the world. Phathom Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Phathom Pharmaceuticals's Market Capitalization

Phathom Pharmaceuticals's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Phathom Pharmaceuticals's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Phathom Pharmaceuticals's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Phathom Pharmaceuticals’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Phathom Pharmaceuticals stock

What is the current Phathom Pharmaceuticals market capitalization?

The current market capitalization of Phathom Pharmaceuticals is 824.73 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Phathom Pharmaceuticals.

How has the market capitalization of Phathom Pharmaceuticals developed in recent years?

The market capitalization of Phathom Pharmaceuticals has increased/decreased by 80.27% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Phathom Pharmaceuticals?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Phathom Pharmaceuticals?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Phathom Pharmaceuticals have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Phathom Pharmaceuticals pay?

Over the past 12 months, Phathom Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Phathom Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Phathom Pharmaceuticals?

The current dividend yield of Phathom Pharmaceuticals is .

When does Phathom Pharmaceuticals pay dividends?

Phathom Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Phathom Pharmaceuticals?

Phathom Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Phathom Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Phathom Pharmaceuticals located?

Phathom Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Phathom Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Phathom Pharmaceuticals from 10/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/20/2024.

When did Phathom Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/20/2024.

What was the dividend of Phathom Pharmaceuticals in the year 2023?

In the year 2023, Phathom Pharmaceuticals distributed 0 USD as dividends.

In which currency does Phathom Pharmaceuticals pay out the dividend?

The dividends of Phathom Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Phathom Pharmaceuticals

Our stock analysis for Phathom Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Phathom Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.